Abstract
high dose VitD3 were significantly decreased (P< 0.05); the activity of caspase-3, TNF-a, CD40 in all drug intervention groups were significantly decreased (P< 0.01); no significant difference in mRNA expression was found between TNBS group and all drug intervention groups. Rats in continuous high dose VitD3 group had hyperealcemia and serum level of creatinine was significantly increased in continuous high dose VitD3 group when compared with the other groups (P< 0.05). Conclusions: VitD3 can alleviate TNBS induced experimental colitis by regulating T cell immunity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
